Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia

• Catharina Müller-Thomas,
• Martina Rudelius,
• Ina-Christine Rondak,
• Torsten Haferlach,
• Julie Schanz,
• Christina Huberle,
• Burkhard Schmidt,
• Rainer Blaser,
• Marcus Kremer,
• Christian Peschel,
• Ulrich Germing,
• Uwe Platzbecker,
• Katharina Götze

Affiliations

Catharina Müller-Thomas

III. Department of Medicine, Technical University of Munich, Munich

Martina Rudelius

Institute of Pathology, Julius-Maximilians-University Würzburg, Munich

Ina-Christine Rondak

Institute for Medical Statistics and Epidemiology, Technical University of Munich, Munich

Torsten Haferlach

MLL, Munich Leukemia Laboratory, Munich

Julie Schanz

Department of Hematology and Oncology, Georg-August-University Göttingen, Munich

Christina Huberle

III. Department of Medicine, Technical University of Munich, Munich

Burkhard Schmidt

Hematology and Oncology Pasing, Munich

Rainer Blaser

Institute for Medical Statistics and Epidemiology, Technical University of Munich, Munich

Marcus Kremer

Institute of Pathology Harlaching, Munich

Christian Peschel

III. Department of Medicine, Technical University of Munich, Munich;German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg

Ulrich Germing

Department of Hematology and Oncology, Heinrich-Heine-University Düsseldorfand

Uwe Platzbecker

German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg;I. Department of Medicine, Gustav-Carus-University Dresden, Dresden, Germany

Katharina Götze

III. Department of Medicine, Technical University of Munich, Munich;German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg